Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03501134 · ClinicalTrials.gov registry record
Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 20
- Enrollment target
NCT03501134: Completed study, sponsored by Duke University.
NCT03501134 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03501134 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
This purpose of this study is to describe the effect of Tumor Treating Fields (NovoTTF) on quality of life (QOL), including exercise, sleep quality, and mood, in patients with World Health Organization (WHO) Grade IV malignant glioma who have been prescribed and approved to receive Optune™. This is an observational, longitudinal study, meaning that information about QOL will be collected over time while the patient is using the NovoTTF device (for example, Optune™).
Primary Outcome
Mean change between baseline and week 24 in total physical activity (MET-h/wk) as measured by the Godin Leisure Time Questionnaire
Interventions
- DEVICE NovoTTF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-08-08 |
| Est. Completion | 2021-06-03 |
What the finished NCT03501134 record still lists
NCT03501134 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which NovoTTF is the first listed.
NCT03501134 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03501134 about?
NCT03501134 is a clinical study titled "Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields". This purpose of this study is to describe the effect of Tumor Treating Fields (NovoTTF) on quality of life (QOL), including exercise, sleep quality, and mood, in patients with World Health Organization (WHO) Grade IV malignant glioma who have been prescribed and approved to receive Optune™. This is ...
What is the current status of trial NCT03501134?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2018-08-08. Estimated completion is 2021-06-03.
What interventions are being tested in trial NCT03501134?
The interventions under investigation include: NovoTTF (DEVICE).
Who is sponsoring clinical trial NCT03501134?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI